Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Avalon GloboCare successfully co-develops novel platform of S-layer coated emulsome technology for next-generation drug delivery and cellular immunotherapy

The company has partnered with Professor Uwe Sleytr of the University of Natural Resources and Life Sciences in Vienna to develop the SLET platform

Avalon GloboCare Corp (NASDAQ:AVCO). has successfully co-developed a novel platform of S-layer coated emulsome technology (SLET) for next-generation drug delivery and cellular immunotherapy.

Avalon said it has partnered with Professor Uwe Sleytr of the University of Natural Resources and Life Sciences (BOKU) in Vienna to develop the SLET platform. And both have jointly filed US and international PCT patent applications for the novel SLET platform.

Avalon noted that, as a vesicular nano-carrier system, emulsomes are composed of an internal lipoidal core surrounded by phospholipid multilayers.

READ: Avalon GloboCare announces co-development of in-silico system to expand ability to design and produce novel cell membrane proteins

This emulsome nano-carrier, when loaded with bio-active agents (such as poorly water-soluble pharmaceuticals and genetic materials, including DNA and RNA), may increase their solubility and bioavailability. This nano-formulation is also designed to be safe and nontoxic.

Avalon said the SLET platform exploits the S-layer fusion proteins as coating materials for the emulsome nano-carriers in order to provide a “molecular GPS system” to guide the trafficking and delivery of the emulsomal payload to a targeted destination in the body.

Avalon noted that is actively exploring the practical uses of SLET, including targeted drug delivery, vaccine development, diagnostic devices, and cellular therapeutic applications.

“We are very excited to announce this novel SLET platform, which we believe will help accelerate the development of our mRNA-based Flash-CAR program,” said Avalon CEO Dr David Jin in a statement.

“The targeted delivery of mRNA to immune effector cells by SLET could open the door to a whole new generation of cancer immunotherapy. In addition, we see a number of other therapeutic and diagnostic applications for this broad and potentially transformative technology platform. Moreover, we believe these latest patent filings will provide us robust international IP protection for this technology and its many potential applications.”

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK